ISPOR’s Top 10 HEOR Trends for 2024-2025

By Staff Writer

January 12, 2024

Introduction:

The International Society for Health Economics and Outcomes Research (ISPOR) recently released its biennial report detailing the top 10 Health Economics and Outcomes Research (HEOR) trends for 2024-2025. This report, the fifth of its kind, offers a compelling glimpse into the future of healthcare. Providing key trends such as Real-World Evidence (RWE), drug pricing, and Artificial Intelligence (AI) taking centre stage.

The Dominance of Real-World Evidence:

RWE has consistently featured in ISPOR’s reports, therefore appearing as the top trend in the three most recent publications. It is increasingly being used to supplement Randomised Controlled Trials (RCTs) in healthcare decision-making, highlighting its growing significance in the industry.

The Recurring Theme of Drug Pricing:

Drug pricing remains a critical concern, featuring as the second trend in the report. However, the introduction of the Inflation Reduction Act (IRA) in the United States, which allows Medicare to negotiate drug prices, could potentially impact global drug development and innovation.

The Rise of Artificial Intelligence:

AI, the third trend, is becoming an integral part of our daily lives and the healthcare sector. From chatbots to machine learning, AI is being utilised in various ways to provide valuable insights in HEOR.

Balancing Innovation and Affordability:

Furthermore, the fourth trend focuses on fostering innovation while ensuring affordable pricing. This balance is vital for the development of new technologies in the healthcare sector.

In conclusion, the ISPOR HEOR trends report presents a comprehensive overview of the top trends shaping the future of healthcare. As pressures on healthcare systems worldwide continue to increase, these trends provide invaluable insights for stakeholders to inform and improve healthcare decisions.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.